Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 119Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 61atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × cirmtuzumab × 1 year × Clear all
NCT02860676 2025-12-15

Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

University of California, San Diego

Phase 1 Completed
3 enrolled 8 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02776917 2025-08-07

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

University of California, San Diego

Phase 1 Completed
23 enrolled 10 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡